Day: August 14, 2020

Tampa, FL, Aug. 14, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — B2Digital Incorporated (the “Company” or “B2Digital”) (OTCMKTS:BTDG), the premier development league for mixed martial arts (“MMA”), is excited to announce that Greg P. Bell, the Company’s Chairman & CEO, and Chris Lytle, Executive in charge of Fighter Development and the B2 Official Training Facilities Network, are featured in a new audio interview on The Stock Day Podcast.The interview can be found here.In the interview, Mr. Bell discusses the Company’s overall business model, including its multiple revenue streams, across live events and fighter training resources and facilities, as well as B2Digital’s growth and stability strategy, pulling in revenues during the virus and staging the potential for explosive growth as the context normalizes....

DENVER, Aug. 14, 2020 (GLOBE NEWSWIRE) — Assure Holdings Corp. (the “Company” or “Assure”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (“IONM”), has appointed Gary Bennett to the newly created position of vice president of revenue.Bennett will be a key member of Assure’s leadership and sales team and will be responsible for planning, scaling, directing and evaluating revenue opportunities. His responsibilities include developing strategies to maximize revenue from all sources and building a platform for selling to hospitals directly as an outsourced provider of IONM services. In addition, Bennett will manage the sales team and implement strategies that ensure revenue and cash collection expectations are met.“Gary’s 30 years of experience in sales management, medical device sales, marketing and...

On track to report potentially pivotal Phase 2 Huntington’s disease topline data by early OctoberPhase 1/2 trial of pepinemab in Alzheimer’s disease to begin enrolling patients in SeptemberRaised net proceeds of $19.8 million since June 30ROCHESTER, N.Y., Aug. 14, 2020 (GLOBE NEWSWIRE) — Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Huntington’s disease and cancer, today announced financial results for the second quarter ended June 30, 2020 and provided a corporate update.Pepinemab Clinical Updates:Huntington’s Disease. The company’s ongoing SIGNAL clinical trial is evaluating its lead drug candidate, pepinemab, for the treatment of Huntington’s disease (HD). The company remains on track to complete the trial within the previously announced time frame....

Stabilizing CashCOLUMBUS, OH, Aug. 14, 2020 (GLOBE NEWSWIRE) — Intellinetics, Inc. (OTCQB: INLX), a cloud-based document solutions provider, announced financial results for the three and six months ended June 30, 2020.2020 Second Quarter Financial HighlightsTotal Revenue increased 187% from the same period in 2019.Software as a Service Revenue increased 8% from the same period in 2019.Net Loss of $282,356 decreased from the same period in 2019.Adjusted EBITDA of $103,974, an improvement of $267,694 compared to an adjusted EBITDA loss of $163,720 from the same period in 2019.2020 Six Month Financial HighlightsTotal Revenue increased 164% from the same period in 2019.Software as a Service Revenue increased 11% from the same period in 2019.Net Loss of $928,567 decreased from the same period in 2019.Adjusted EBITDA of $384,264, an improvement...

VANCOUVER, British Columbia, Aug. 14, 2020 (GLOBE NEWSWIRE) — The Sonora Gold project (“The Project”) is located 110 Km due north from Hermosillo, in Sonora, Mexico and 140 Km south of Tucson, Arizona, USA. The project area has very good infrastructure, highway access, available power, skilled labor, etc. The project concessions cover a continuous area of 6000 Hectares.The project is located within the Mojave-Sonora megashear, a district wide geological fault zone that consists of a series of left-lateral strike slip faults that trend NW-SE. The Mojave-Sonora megashear formed in the mid-to-late Jurassic and is mapped from the Mojave Desert in California, across Northern Mexico, to the Gulf of Mexico.In the state of Sonora in Northern Mexico, the Mojave-Sonora megashear fault system is locally known as the Mojave Fault. The Mojave...

BUENA, N.J., Aug. 14, 2020 (GLOBE NEWSWIRE) — Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, announced they will hold a conference call at 8:00AM ET on Wednesday August 19th, 2020 to discuss the 2nd quarter 2020 financial results and business update.The Company invites you to listen to the call by dialing (866) 393-8366.  International participants should call (409) 350-3154.  Participants should ask to join the Teligent, Inc. call.This call is available via webcast and can be accessed under News & Events in the Investor Relations section of Teligent, Inc.’s website at www.teligent.com.About Teligent, Inc.Teligent is a specialty generic pharmaceutical company.  Our mission is to be a leading player in the specialty generic prescription drug market.  Learn more on our website...

TORONTO, Aug. 14, 2020 (GLOBE NEWSWIRE) — Unisync Corp. (TSX: “UNI”) (the “Company”) operates through two business segments: Unisync Group Limited (“UGL”) headquartered in Mississauga, Ontario and Peerless Garments LP (“Peerless”) based in Winnipeg, Manitoba.Consolidated revenue for the three months ended June 30, 2020 (“Q3 2020”) of $17.2 million decreased by $4.4 million or 20% over the three months ended June 30, 2019 (“Q3 2019”) on a $5.5 million revenue drop in the UGL segment partially offset by a $1.1 million revenue improvement in the Peerless segment. Revenue for the 9 month period ended June 30, 2020 of $72.0 million was 25% higher than the $57.6 million reported for the same period last year.UGL segment revenue of $12.2 million decreased by 31% over Q3 2019 caused by the impact of the COVID-19 pandemic...

YARDLEY, Pa., Aug. 14, 2020 (GLOBE NEWSWIRE) — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, today announced the pricing of its previously announced public offering of 6,000,000 shares of common stock at a price to the public of $5.85 per share. All of the shares of common stock will be offered by Optinose. Optinose also granted the underwriter a 30-day option to purchase up to an additional 900,000 shares of common stock. The offering is expected to close on August 18, 2020, subject to satisfaction of customary closing conditions.Optinose intends to use the net proceeds of the offering for working capital and general corporate purposes, including the commercialization of XHANCE, the clinical development of XHANCE for a follow‑on indication for the treatment...